Canadian researchers have reported positive results from a trial of a molecule that can multiply the number of stem cells in umbilical cord blood units for transplantation.
The molecule, UM171, was tested in a phase 1-2 trial by a team of researchers led by Dr Guy Sauvageau at the University of Montreal, Canada. Out of 27 adult patients with bone marrow cancers recruited, 22 patients received single cord blood unit transplants which had been expanded with UM171.
These patients showed lower mortality rates and risk of graft versus host disease than expected. The results of the trial appeared recently in the journal Lancet Haematology.
Dr Sauvageau says: “Although the rate of graft versus host disease when using umbilical...
1 day ago
Canadian researchers have reported positive results from a trial of a molecule that can multiply the number of stem cells in umbilical cord blood units for transplantation.
The molecule, UM171, was tested in a phase 1-2 trial by...
1 day ago
Older patients with blood cancers who are being considered for stem cell transplantation experience better outcomes and survival rates if they undergo a multidisciplinary evaluation first, a US study has found.
Research led by a...
1 day ago